Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.
Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.
Company Details
- Employees
- 15
- Founded
- -
- Address
- 7750 El Camino Real,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.palisadebio.com/
- Keywords
- Therapeutics, Drug Development, Gastrobiome, Microbiome, Surgery, Cardiovascular, Gastrointestinal, Biotech, R&D, COVID-19.
- HQ
- Carlsbad, California
Palisade Bio Questions
Palisade Bio's website is https://www.palisadebio.com/
Palisade Bio's LinkedIn profile is https://www.linkedin.com/company/palisadebio
Palisade Bio has
15 employees.
View email and phone details for 15
employees at Palisade Bio.
Palisade Bio's industry is
Pharmaceutical Manufacturing
Palisade Bio's top competitors are
Biora Therapeutics,
Qualigen Therapeutics,
Finch Therapeutics,
Lineage Cell Therapeutics,
Dogwood Therapeutics,
Neurocrine Biosciences,
Giiant Pharma Inc.,
Ionis Pharmaceuticals, Inc.,
Moleculin Biotech, Inc.,
Scynexis, Inc..
Palisade Bio's categories are Pharmaceutical Manufacturing
Palisade Bio's founding year is 2005
